Twenty‐one evaluable patients received second‐line chemotherapy for recurrent ovarian adenocarcinoma with induction Cisplatin given weekly followed by monthly combination chemotherapy. Forty‐two percent of the patients responded to induction weekly Cisplatin. Of the responders, 77% are alive as compared to only 8% of the nonresponders. Maintenance of the responses by monthly combination chemotherapy remains a significant problem. Moreover, 83% and 70% of patients who received weekly Cisplatin as first‐ and third‐line induction chemotherapy, respectively, had objective responses. Of the total 43 patients who received weekly Cisplatin as first‐, second‐, or third‐line chemotherapy, 60% responded, including complete clinical responses in 14% and partial responses in 46%.